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Osteosarcoma poses serious �arzard to c�ildren’s 
�ealt�. It affects 5.6 per million c�ildren younger t�an 
15 years annually� wit� a peak incidence occurring 
in t�e second decade of life [1]. It arises from mes-
enc�ymal bone-forming cells and most commonly 
affects t�e metap�yseal growt� plate of long bones. 
T�e formation of new blood vessels is a fundamental 
biological process t�at plays a critical role in t�e pat�o-
genesis of osteosarcoma.
Vascular endot�elial growt� factor �VEGF� �as been 
demonstrated to be a key mediator of angiogenesis 
in many models. Previous studies s�owed t�at �ig� 
indexes of VEGF expression were significantly associ-
ated wit� osteosarcoma recurrence� metastasis and 
deat�. But most of t�e researc�es� w�o studied VEGF� 
focused only on endot�elial cells/angiogenesis.
RNA interference �RNAi�, as commonly defined� 
is a p�enomenon leading to posttranscriptional gene 
silencing �PTGS� after endogenous production or arti-
ficial introduction into a cell of small interfering double 
strand RNA �siRNA� wit� sequences complementary 
to t�e targeted gene. Compared wit� t�ose tradition-
ally used for antisense DNA-mediated suppression of 
gene expression� RNAi �as many superiorities suc� as 
its efficiency� precision� versatility� speed and cost-ef-
fectiveness [���]. Studies �ave s�own t�at synt�etic 
�1��� bp-long siRNAs can be used to silence bot� 
exogenous and endogenous gene expression in 
mammalian cells [5�6]. Z�ang et al. [7] pointed out 
t�at RNAi provides a novel tool to study t�e function 
of various VEGF isoforms and may contribute to VEGF 
isoform-specific treatment in cancer.
In t�is study� we in�ibited t�e vascular endot�elial 
growt� factor gene expression using RNAi tec�nique 
and explored its influence on t�e apoptosis� prolifera-
tion and vasculogenic mimicry of osteosarcoma cell 
in vitro.
MATERIALS AND METHODS
Reagents. In t�e study Dulbecco’s minimal essen-
tial medium �D�E��� �.�5% trypsin� 1�% fetal bovine 
serum �GIBCO� USA�� �atrigel�collagen� Annexin 
V-FITC Apoptosis Detection Kit� Type I collagen �BD� 
USA�� Effectene Transfection Reagent �Qiagen� Ger-
many�� DNA polymerase� restriction endonuclease� 
T� DNA ligase �TaKaRa� Japan�� secondary peroxi-
dase-conjugated goat antimouse antibodies �Beijing 
Dingguo� C�ina�� primary anti-VEGF antibodies �R&D� 
USA�� �TT� acrylamide� TE�ED� ammonium persulfate 
�Sigma� USA�� pSilencer neo �Ambion� USA�� E. coli 
XLI-Blue �Department of Bioc�emistry� Fudan Univer-
sity� C�ina� were used.
Construction of specific siRNA targeting 
VEGF. According to optimization principle of siRNA� 
we designed 1�nt sequence-specific siRNA targeting 
VEGF [5]. All c�emically synt�esized oligonucleotides 
were obtained from S�ang�ai S�enyou Company. 
DNA sequences of t�e double-stranded siRNAs are 
as follows:
sense: ‘GATCCCGGCCAGCACATAGGAGAGATTCA-
AGAGATCTCTCCTATGTGCTGGCCTTTTTTGGAAA-�’;
antisense: ‘GCCGGTCGTGTATCCTCTCTAAGTTCTCT 
AGAGAGGATACACGACCGGAAAAAACCTTTTCGA-5’.
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According to t�e manufacturer directions� t�e pro-
ducts were p�osp�orylated� annealed, ligated wit� 
T�DNA ligase to DNA plasmid and transformed 
to bacteria. T�e colonies were amplified and purified 
using a miniprep purification kit after transformation. 
First� plasmid DNAs were incised and verified on 
an 15% nondenaturing polyacrylamide gel. T�en� t�e 
correctly sized plasmid DNAs were sequenced. After 
t�ose proof-tests� t�e plasmid DNAs wit� correct se-
quences were purified wit� QIAGEN �axi Plasmid DNA 
kit and used to transfect �G6� cells in t�e following 
experiments. 
Cell culture. Osteosarcoma cell line of �G6� 
�American Typical Culture Collection� was cultured 
in D�E� medium� containing 1�% �v/v� �eat-inacti-
vated fetal calf serum and maintained at �7 °C in an in-
cubator containing 5% CO�.T�e cells were �arvested 
at monolayer confluence wit� �.�5% trypsin — 1 m� 
EDTA� and subcultured for following experiments.
siRNA transfection. �G6� cells �7.5 × 1�5� were 
seeded in �5 mm plates wit� 1 mL D�E� and �G6� 
cells �1×1��� were seeded in �6 well plates wit� 1�� µL 
D�E�. After incubation to ac�ieve �����% conflu-
ence� �G6� cells were transfected wit� siRNA accor-
ding to t�e manufacturer’s instructions.
Three-dimensional culture of osteosarcoma 
cells. As amended by �ontesano [7]� type I col-
lagen was prepared. For all experiments� 5�� µl of 
�atrigel or type I collagen �Collaborative Biomedi-
cal� were dropped onto glass coverslips and allowed 
to polymerize for 1 � at �7 °C. After t�e transfection� 
�G6� cells �7.5×1�5/ml� were seeded on t�e top 
of t�e gels respectively and supplemented wit� D�E� 
medium� containing 1�% �v/v� of �eat-inactivated 
fetal calf serum. Fres� medium was replaced every 
day and cultured �G6� cells were observed during 
t�e 1st week.
Hematoxylin and eosin (HE) staining. Glass 
coverslips wit� sample of t�ree-dimensional culture 
were taken out after one-week culture. T�e samples 
were fixed wit� buffered formalin� embedd into paraf-
fin and t�in sections were cut. Sections were stained 
wit� �ematoxylin and eosin and analyzed using lig�t 
microscopy.
Western blotting. Osteosarcoma cells and t�e 
medium� in w�ic� t�ey were �arvested� were placed 
in 1�� µL buffer �Tris� NaCl� ��% Triton-X-1��� and 
protease in�ibitors�/6� mm plate. Immediately af-
terwards� cell samples were sonicated on ice and 
incubated for 5 min at �5 °C before centrifugation. T�e 
protein content was measured� and samples applied to 
15% PAGE� followed by transfer to polyvinylidene diflu-
oride �PVDF� membrane. �embranes were blocked by 
5% milk in PBST for 1 � at room temperature� followed 
by overnig�t incubation wit� VEGF primary antibody 
at � °C in a concentration 1 : 1���. T�e incubation wit� 
secondary antibody was done for � � at RT� after w�ic� 
t�e membranes was was�ed in PBST. �embranes 
were exposed to a c�emiluminescence reagent and 
t�e c�emiluminescence was captured on X-ray film 
over exposure times to determine t�e optimal expo-
sure time. Protein concentrations were analyzed by 
densitometry.
MTT. �G6� cells �1 × 1��� were seeded in �6 well 
plates wit� 1 mL of D�E� and incubated to �����% 
confluence. After transfection� cells were cultured for 
�� �� 7� �� and �6 �. 5 mg/ml of �TT was added to eac� 
well� and incubation was continued at �7 °C for � �. T�e 
content of eac� well was removed� and 15� µl of D�SO 
was added to extract t�e dye. After gentle agitation� 
t�e optical density �OD� was measured wit� a enzyme-
linked immune instrument. Cell culture experiments 
were performed in triplicate. In�ibitory effect of pSi-
lencer-VEGF on proliferation of osteosarcoma cells 
was calculated by following equation: in�ibitory rate 
of cells ={ �OD control wells � OD treated wells� / OD 
control wells} × 1��%.
Apoptosis assays. To analyze t�e cells for ap-
optosis� osteosarcoma cells �� × 1�6� including t�e 
cells in t�e medium were �arvested on t�e t�ird day 
after transfection. T�e cells were trypsinized� pelleted� 
was�ed in PBS� and resuspended in 1xbinding buffer 
containing conjugated annexin-V �Annexin-V-FITC� 
antibody and propidium iodide �PI� according to t�e 
manufacturer’s protocol. T�e cells wit�out Annexin-
V-FITC and PI were used as negative controls. T�e 
foregoing samples were analyzed by flow cytometry.
Statistical Analysis. Data analysis was performed 
wit� medical SAS6.1�. Statistical significance was 
assessed wit� Students t-test. Data is presented as 
mean ± standard deviation �SD� and p < �.�5 was 
considered to be statistically significant.
RESULTS
pSilencer-VEGF siRNA expressing plasmid. Ini-
tially� plasmid DNAs were incised and verified in a 15% 
non-denaturing polyacrylamide gel �data not s�own�. 
Furt�er� t�e correct plasmid DNAs were sequenced. 
T�e presence of siRNA inserted sequence was con-
firmed� and t�ere were no mutations in t�e insert to 
pSilencer plasmid. Additionally� we could see unmodi-
fied H1-RNA promoter� BamH I and Hind III restriction 
sites wit�in t�e cloned insert as s�own on Fig. 1.
Fig. 1. T�e results of pSilencer-VEGF DNA sequencing
Western blotting. VEGF expressed in at least six 
isoforms wit� distinct biologic activities and clinical 
implications. Western blotting results s�owed t�at 
four isoforms of VEGF expressed in osteosarcoma 
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cells� and VEGF165 was t�e predominant isoform in t�e 
medium. VEGF expression in �G6� cells was reduced 
on t�e �nd and �rd day after pSilencer-VEGF siRNA 
transfection compared wit� control group. In medium� 
VEGF protein expression in �G6� cells transfected by 
pSilencer-VEGF was significantly decreased in com-
parison wit� non-treated cells or treated by pSilencer. 
However� VEGF protein expression level did not differ 
between non-transfected and transfected by pSilencer 
cells as s�own by Western blotting �Fig. ��.
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Fig. 2. T�e expression of VEGF protein after transfecting pSi-
lencer-VEGF to osteosarcoma cells� Western blotting. �Lanes 
1�6 are normal cells and media� media and cells transfected 
by pSilencer� cells and media transfected by pSilencer- VEGF 
siRNA� respectively�
MTT. T�e absorbance value of �G6� cells treated 
wit� pSilencer-VEGF s�owed decreased prolifera-
tion as measured by �TT compared wit� �G6� cells 
treated wit� pSilencer� and t�ere was significant dif-
ference between t�e absorbance value of two groups 
at �� �� 7� �� and �6 �.
In�ibitory effect of pSilencer-VEGF on proliferation 
of osteosarcoma cells wit� �TT were �1.67%� ��.��%� 
�5.��% at �� �� 7� �� �6 � respectively �Fig. ��.
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Fig. 3. In�ibitory effect of pSilencer-VEGF on proliferation 
of osteosarcoma cells
Apoptosis and proliferation of osteosarcoma 
cells examined by light microscopy. As s�own on 
Fig. �� transfection of pSilencer did not induce any 
obvious c�anges in t�e s�ape of �G6� cells. T�e 
cells outspreaded t�emselves� �ad an asteroidal or 
polygonal appearance� contacted tig�tness and �ad 
t�e ability for overlapping growt� like fibroblasts in 
morp�ology. However� t�e morp�ology dramatically 
c�anged to an elongated s�ape wit� filamentous pro-
trusions after �� � upon transfection by pSilencer-
VEGF. Some cells were morp�ologically c�aracterized 
by severe alterations in s�ape like cell s�rinkage and 
disintegration of cell-cell contacts. S�uttle-s�aped 
appearance� line sparseness and slow growt� were 
also obviously observed.
Apoptosis assays using Annexin-V FITC/Pro-
pidium Iodide Staining. Apoptosis was induced in 
osteosarcoma cells after transfection of pSilencer-
VEGF as s�own on Fig. 5. Apoptosis assays revealed 
t�at pSilencer-VEGF induced apoptosis in ��.�7% 
osteosarcoma cells upon culturing for ���7� �.
a
b
Fig. 4. Effect of pSilencer-VEGF on apoptosis and proliferation 
of osteosarcoma cells wit� lig�t microscopy: �a) �G6� cells 
transfected by pSilencer �× ����; �b) �G6� cells transfected by 
pSilencer-VEGF �× ����
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Fig. 5. Effect of pSilencer-VEGF on apoptosis of osteosarcoma 
cells
Vasculogenic mimicry and the structures 
MG63 cells formed were observed in Matrigel cul-
ture. �G6� cells formed t�e tubular networks as well 
as endot�elial cells did after transfection by pSilencer. 
In contrast� �G6� cells did not form structures of t�e 
tubular networks after transfection by pSilencer-VEGF 
�Fig. 6�.
Vasculogenic mimicry and the tube formation 
MG63 cells formed in type I collagen culture. T�e 
conglomeration of �G6� cells involved in tube for-
mation was detectable in type I collagen culture after 
transfection by pSilencer for two days. T�en� �G6� 
cells were incubated furt�er up to one week period� 
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w�en t�e structures of t�e tubular networks were ob-
served. At t�e same time� �G6� cells could not form 
structures of t�e tubular networks in one week after 
transfection by pSilencer-VEGF �Fig. 7�.
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Fig. 6. T�e structures formed by �G6� cells were studied 
in �atrigel culture wit� p�ase contrast microscopy �� � after 
transfection: �a) T�e structures of t�e tubular networks were 
not formed by �G6� cells after transfection by pSilencer-VEGF 
�× ����; (b) T�e structures of t�e tubular networks� w�ic� �G6� 
cells formed after transfection by pSilencer �× ����
The cross sections of tubules formed by MG63 
cells were observed in type I collagen culture with 
phase contrast microscope and HE staining. �G6� 
cells transfected by pSilencer formed t�e tubular 
networks in t�e intersecting plane of type I collagen. 
Adversely� �G6� cells could not form t�e tubular net-
works in t�e sections of type I collagen one week after 
transfection of pSilencer-VEGF �Fig. ��.
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Fig. 7. T�e structures t�at �G6� cells formed were analyzed in 
type I collagen culture wit� p�ase contrast microscopy: (a) Struc-
tures of t�e tubular networks were not formed by cells transfected 
wit� pSilencer-VEGF in one week �× ����; (b) T�e conglomera-
tion of t�e �G6� cells in two days after transfection by pSilencer 
�× ����; (с) T�e structures of t�e tubular networks t�at �G6� cells 
formed after transfection by pSilencer inone week �× 6���
DISCUSSION
Osteosarcoma is t�e most common �ig�ly malignant 
bone tumor in c�ildren and adolescents. Limb-salvage 
resection and neoadjuvant c�emot�erapy or amputation 
is t�e usual treatment of c�oice wit� t�e 5-year survival 
rate being between ��% to 7�%. Several studies demon-
strated t�at vascular genesis mig�t be involved in growt� 
and development of osteosarcoma. W�en new vascular 
networks are formed or expanded� tumor spreads almost 
exclusively via t�e bloodstream. VEGF is an important 
regulator of angiogenesis and vasculogenesis [�� �]� 
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w�ic� ex�ibits endot�elial cell-specific mitogenic prop-
erties. T�ere is considerable experimental evidence t�at 
VEGF isoforms are strongly involved in neoangiogenesis 
of neoplastic cells� extracellular matrix remodeling� 
inflammatory cytokine regeneration� formation of an 
invasive and metastatic immunop�enotype. VEGF is bot� 
a vascular growt� and vascular permeability promoter. 
Its expression can upregulate several proangiogenic and 
prometastatic molecules. VEGF expression in untreated 
osteosarcoma is predictive marker for pulmonary metas-
tasis and poor prognosis.
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Fig. 8. Tubular networks formed by �G6� cells in type I col-
lagen culture and analyzed wit� HE stainingfollowed by p�ase 
contrast microscopy: (a) T�ere was no tubular networks forma-
tion in a week after transfection by pSilencer-VEGF �× ����; 
(b) T�e structures of t�e tubular networks� w�ic� �G6� cells 
formed in a week after transfection by pSilencer �× ����
Anti-angiogenesis t�erapy targeting VEGF is inferior 
to RNAi in silencing t�e target gene or establis�ing t�e 
functions of gene efficiently and differentially. RNA inter-
ference met�ods provide several major advantages over 
standard met�ods �antisense DNA or antibody-based 
tec�niques� for suppressing gene expression [1�� 1�]. 
Our current studies� confirmed by reverse-transcriptase 
polymerase c�ain reaction �RT-PCR� analyses and 
Westen blotting� s�owed t�at VEGF isoforms and t�eir 
receptors were expressed in osteosarcoma cells� wit� 
VEGF165 being t�e predominant form in medium.
It �as been discussed previously t�at expanding of t�e 
tumor endot�elial mass results in t�e de novo formation 
of endot�elial cell-lined vessels. In response� tumor-de-
rived angiogenic factors� suc� as VEGF� support tumor 
growt� and angiogenesis in a paracrine fas�ion. Induc-
tion of apoptosis of tumor cells is caused by suppressive 
vascular formation in anti-angiogenesis treatment. Our 
previous data [1�] demonstrated t�at osteosarcoma cells 
not only produced VEGF� but also acquired t�e capacity 
to express functional receptor �suc� as VEGFRs�� w�ic� 
resulted in t�e generation of an autocrine loop� independ-
ent of endot�elial cells t�at supported osteosarcoma 
cells proliferation� in�ibited apoptosis and promoted 
vasculogenic mimicry. Recently� researc�es �ave s�own 
t�at interaction of VEGF wit� particular subtypes of 
receptors� w�ic� all possess an internal tyrosin kinase 
domain� activates a circuit of signaling pat�ways� e.g. 
PI�K/Akt� Ras/Raf-�EK/Erk� eNOS/NO� and IP�/Ca�+ 
[1�]. In addition� VEGF decreased t�e expression of gene 
products involved in anti-apoptosis �xIAP� Bcl-�� HIF-1� 
and survivin� and proliferation �cyclin D1 and c-�yc� 
[15� 16]. T�ese proteins participate in t�e generation of 
specific biological responses connected wit� cellular 
proliferation� cell cycle progression� viability� motility� 
neovascularization or increasing vascular permeability. 
Furt�ermore� as one of t�e immune suppressive factors� 
VEGFs induced immature myeloid cells and regulatory 
T-cells in accordance wit� tumor progression� resulting 
in t�e in�ibition of dendritic cell maturation and T-cell 
activation in a tumor-specific immune response [17].
Previously� we �ad also demonstrated t�e presence 
of osteosarcoma cells expressing t�e gene markers as-
sociated wit� tumor vasculogenic mimicry in vitro [1�]. 
We �ad also described t�at t�e formation of t�e vascular 
lumen of osteosacoma cells was remarkably similar to 
lumen formation in epit�elial cells. Hig�ly aggressive 
cancer cells line vascular c�annels and form a perfused 
network in t�e absence of endot�elial cells w�ic� are 
independent of tumor angiogenesis. As a result� vas-
culogenic mimicry secures t�at t�e newly regenerated 
portion of tissue develops in parallel wit� t�e appropriate 
vascular supply. Proteinases secreted by tumor cells 
activation causes local degradation of extracellular 
matrix components of t�e vascular c�annels� so t�at 
tumor cells contacted t�e rapid blood flow of tumor. It 
is conceivable t�at vasculogenic mi micry is in favor of 
t�e growt� invasion and metastasis.
Our findings suggest t�at down-regulation of VEGF 
expression �as two functions: not only in�ibits prolifer-
ation and induces apoptosis� but also markedly in�ibits 
vascular cord and tube formation of osteosacoma 
cells. It may be implemented from t�e obstruction of 
tyrosine kinase receptor signal. Oda et al. [16] found 
t�at VEGF expression in t�e primary site �ad predic-
tive value for t�e osteosarcoma patients w�o would 
develop lung metastasis. Alt�oug� RNAi gene t�erapy 
�as less side effects� it s�ould not be ignored t�at t�e 
mutant osteosacoma cells mig�t secret ot�er factors 
instead of VEGF� leading to elusive suppression.
Taken toget�er� signal transduction via VEGF may 
play multiple roles in t�e growt� and development 
of osteosarcoma: VEGF not only activates endot�elial 
cells� participates in t�e angiogenesis� vasculogenesis� 
but also activates signal transduction involved in vas-
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culogenic mimicry� proliferation and apoptosis of tumor 
cells t�emselves. Our data indicate t�at t�e in�ibition of 
VEGF expression by siRNA silencing �as t�e potential to 
in�ibit tumor growt� and progression of osteosarcoma. 
A VEGF-based siRNA silencing approac� may become 
a promising treatment for osteosarcoma in t�e future.
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ИНДУКЦИЯ АПОПТОЗА, ИНГИБИРОВАНИЕ ПРОЛИФЕРАЦИИ 
И ВАСКУЛЯРНОЙ МИМИКРИИ КЛЕТОК ОСТЕОСАРКОМЫ 
IN VITRO ПРИ ПРИМЕНЕНИИ siRNA-VEGF
Цель: ингибировать експрессию фактора роста эндотелия сосудов (VEGF) с помощью метода РНК интерференции (RNAi) и 
изучить влияние введения сайленсинга siRNA-VEGF на апоптоз, пролиферацию, васкулярную мимикрию клеток остеосаркомы in 
vitro. Методы: плазмида PSilencer-VEGF, рекомбинированная за счет клонирования специфической siRNA последовательности, 
была трансфецирована в клеточную линию остеосаркомы MG63. Экспрессию VEGF после трансфекции проверяли с помощью 
Вестерн-блот анализа. Биологические особенности трансфецированных клеток MG63, а именно пролиферацию, апоптоз и 
васкулярную мимикрию, изучали с помощью MTТ-анализа, проточной цитофлуориметрии, аннексина V-FITC/пропидиум йодида, 
световой микроскопии и окрашивания гематоксилином и эозином (HE). Результаты: последовательность, клонированная 
в плазмиду pSilencer-VEGF, проверена при секвенировании ДНК. Специфические к VEGF последовательности siRNA 
значительно снижали его экспрессию клетками MG63. В сравнении с клетками, трансфeцированными плазмидой без siRNA, 
рост клеток с PSilencer-VEGF был ингибирован, а также в них был индуцирован ранний апоптоз. Ингибирование экспрессии 
VEGF было ассоциировано со снижением васкулярной мимикрии клеток MG63. Выводы: ген VEGF может быть тесно связан 
с регуляцией апоптоза и пролиферации клеток остеосаркомы и может быть ключевым регулятором васкулярной мимикрии. 
Ингибирование экспрессии VEGF с помощью специфических siRNA можно рассматривать как новый подход к лечению опухолей, 
характеризующихся повышенной экспрессией VEGF, таких как остеосаркома.
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Copyright © Experimental Oncology, 2008
